Speech-Language Pathologists in Spoiane, WA Accepting Medicare
1 Speech-Language Pathologists found. Showing 1 - 1
 Bonnie J Powers, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 310 N. Riverpoint Blvd., Box V, Spoiane, WA 99202 Phone: 509-358-7581 Fax: 509-368-6890 |
News Archive
Canadian women unaware of their vitamin D levels
A new survey, conducted by Ipsos Reid, reveals Canadian women are unaware of their vitamin D levels. According to the survey sponsored by Marc Sorenson, Ed.D, 97 per cent of the 516 Canadian women surveyed didn't know their vitamin D levels.
Study finds link between high levels of dietary AGEs and breast cancer risk
Hollings Cancer Center researchers at the Medical University of South Carolina and colleagues assessed the connection between dietary advanced glycation end products and breast cancer risk in a study first published online March 2020 in Cancer Prevention Research.
State exchanges and health IT could be hurdles to health law implementation
It seemed like a good idea at the time. But a health insurance tax credit for small businesses, part of President Barack Obama's health care law that gets strong support in public opinion polls, has turned out to be a disappointment. Time-consuming to apply for and lacking enough financial reward to make it attractive, the credit was claimed by only 170,300 businesses out of a pool of as many as 4 million potentially eligible companies in 2010.
Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical study
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 8 days ago